Skip to Content

Edurant Approval History

  • FDA approved: Yes (First approved May 20th, 2011)
  • Brand name: Edurant
  • Generic name: rilpivirine
  • Dosage form: Tablets
  • Company: Tibotec Pharmaceuticals
  • Treatment for: HIV Infection

Edurant (rilpivirine) is a non-nucleoside reverse transcriptase inhibitor (NNRTI) indicated in combination with other antiretroviral drugs for the treatment of HIV-1 infection in adults who have never taken HIV therapy (treatment-naïve).

Development History and FDA Approval Process for Edurant

May 20, 2011Approval FDA Approves New HIV Treatment Edurant (rilpivirine)
Jul 26, 2010Tibotec Pharmaceuticals Submits New Drug Application for Investigational Once-Daily HIV Treatment TMC278 to U.S. Food and Drug Administration

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.